Skip to main content

Table 3 Comparison of crude and adjusted hazard ratios (95 % confidence interval) between the baseline and time-varying covariate (TVC) models for all 17 individual Charlson comorbidities

From: Effects of longitudinal changes in Charlson comorbidity on prognostic survival model performance among newly diagnosed patients with hypertension

 

Baseline

TVC

 

cHRa (95 % CI)

aHRb

((95 % CI)

cHRa ((95 % CI)

aHRb

((95 % CI)

 Sex (Male)

1.15 (1.14-1.17

1.23 (1.22-1.26)

1.15 (1.14-1.17)

1.15 (1.14-1.17)

 Age

1.05 (1.05-1.06)

1.04 (1.04-1.04)

1.06 (1.05-1.06)

1.03 (1.03-1.03)

Region of Residence

 Urban

1.01 (.99-1.03)

1.10 (1.08-1.12)

1.01 (.99-1.03)

1.09 (1.07-1.11)

Income Quintile

 (Compared to 1- Lowest)

    

 2

.88 (.86-.90)

.95 (.93-.98)

.88 (.86-.90)

.97 (.95-.99)

 3

.81 (.79-.83)

.92 (.90-.94)

.81 (.79-.83)

.94 (.92-96)

 4

.69 (.67-.71)

.86 (.85-.89)

.69 (.67-.71)

.91 (.88-.95)

 5 – Highest Income Quintile

.65 (.63-.66)

.85 (.82-.87)

.65 (.63-.66)

.93 (.90-.95)

Charlson Comorbidities

 Myocardial infarction

2.2 (2.15-2.25)

1.07 (1.05-1.1)

2.89 (2.84-2.94)

1.2 (1.18-1.22)

 Congestive heart failure

4.19 (4.11-4.27)

1.77 (1.73-1.81)

5.21 (5.13-5.29)

1.88 (1.84-1.92)

 Peripheral vascular disease

2.99 (2.9-3.07)

1.24 (1.2-1.28)

3.31 (3.24-3.38)

1.16 (1.14-1.19)

 Cerebrovascular disease

2.87 (2.8-2.93)

1.28 (1.24-1.31)

3.65 (3.59-3.72)

1.41 (1.38-1.43)

 Hemiplegia or paraplegia

7.64 (7.43-7.85)

2.36 (2.29-2.43)

8.82 (8.66-8.98)

2.89 (2.83-2.95)

 Dementia

1.88 (1.85-1.91)

1.31 (1.29-1.34)

2.16 (2.12-2.19)

1.3 (1.28-1.32)

 Chronic pulmonary disease

1.69 (1.61-1.76)

1.18 (1.13-1.24)

1.62 (1.56-1.67)

1.03 (0.99-1.07)

 Rheumatologic disease

1.67 (1.61-1.73)

1.1 (1.06-1.14)

2.02 (1.96-2.07)

1.1 (1.08-1.13)

 Peptic ulcer disease

2.31 (2.21-2.42)

1.69 (1.6-1.78)

2.66 (2.58-2.74)

1.56 (1.51-1.62)

 Diabetes without chronic complications

2.18 (2.13-2.23)

1.3 (1.27-1.33)

2.16 (2.12-2.2)

1.1 (1.07-1.12)

 Diabetes with chronic complications

3.27 (3.14-3.4)

1.41 (1.35-1.48)

3.8 (3.71-3.9)

1.27 (1.23-1.31)

 Renal disease

3.45 (3.28-3.62)

1.44 (1.36-1.52)

4.18 (4.04-4.33)

1.36 (1.31-1.41)

 Any malignancy, including leukemia and lymphoma

3.52 (3.41-3.64)

1.63 (1.57-1.69)

4.78 (4.68-4.87)

1.72 (1.69-1.76)

 Metastatic solid tumor

3.11 (3.04-3.18)

1.5 (1.47-1.54)

4.49 (4.42-4.57)

1.87 (1.83-1.90)

 Mild liver disease

5.7 (5.23-6.21)

1.97 (1.79-2.17)

7.1 (6.73-7.49)

2.1 (1.98-2.23)

 Moderate or severe liver disease

8.34 (8.04-8.65)

3.58 (3.43-3.73)

13.26 (12.99-13.53)

5.15 (5.03-5.28)

 AIDS/HIV

1.86 (1.42-2.44)

1.72 (1.28-2.31)

2 (1.62-2.46)

1.65 (1.32-2.06)

  1. acHR crude hazard ratio AIC Akaike Information Criterion
  2. baHR adjusted hazard ratio-adjusted model included sex age area of residence and median household income